Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Here is a article discussing PF-655 from Quark pharma in phase II (diabetic macular edema) expected to be announced in 1-2months time. If it is successful, Silence therapeutics gets a £4M milestone payment (plus higher milestone payments at phase III, and sales royalties). I think it's second attempt at a higher dose (3mg) may be successful. http://www.fool.com/investing/general/2014/03/19/why-pfizer-investors-should-watch-quark-this-summe.aspx
Quark pharma successfully complete phase II trial (delayed graft function using AtuRNAi-enabled QPI-1002. Which means royalty payments for silence therapeutics (AtuRNAi developed and licenced by silence) at some point. http://www.marketwatch.com/story/quark-announces-completion-of-phase-ii-trial-evaluating-qpi-1002-for-prevention-of-delayed-graft-function-in-kidney-transplant-patients-2014-07-01
Interesting piece on silence therapeutics IP on RNAi trigger mechanisms http://rnaitherapeutics.blogspot.fi/2014/07/rnai-trigger-history-revisited-as.html
expect a deal of movement 7 days to go.
i think you're right. I was looking at the chart for US peer, Alnylam today. It has started to rebuild very nicely over the last month or so since the growth stock 'correction' earlier in the year. As a reminder, Alnylam's market cap is north of $5bn. We're struggling to make $200mn?! The other US 'peer' is Dicerna but that's at an earlier stage of development compared to the other two and its chart remains effectively broken after an overly enthusiastic IPO debut at the start of the year...
Good to see some volume, thought you were all asleep. What's the cause, event however? No RNS.
BEWARE
If you read between the lines of the CEO's previous press release, it appears that some of the "billions of dollars" in investment in similar companies in the USA may well be finding their way through to a takeover of SLN...SLN has a unique set of propriety technology that is essential to some its US counterparts...all I can say is watch this space....
more fun though
off obvious support
reading my comments; or is the takeover scenario a possibility??!!
wonder if SLN is a potential for being taken over, if the big companies are looking to increase their pipeline?
video interview Silence Therapeutics morphing into commercial drug company Ali Mortazavi, chief executive of Silence Therapeutics (LON:SLN) tells Proactive Investors that it is transforming into a product company as it tailors its development technologies into commercial drugs. http://tinyurl.com/qjprdc8
ya what that island reversal at the exact top was spot on !
drop looks like people sorting out their CGT for end of year
only just seen this..I think it is highly encouraging
Er, there's no need for histrionics here. Silence, like all growth companies that have momentum, wants/needs capital to grow further/faster. Sure, sometimes companies need capital to survive but that's clearly not the case here. Assuming you trust management to deploy new capital wisely (a key question), it's just plain wrong for any investor to complain when a growth/innovation company like this one issues an RNS like it has done today. If Silence does capital raise, then they also have a chance of bringing some more institutional investors on-board, i.e. investors who cannot build positions under normal trading conditions because of a lack of liquidity. Capital raise? bring it on!!
rns maybe fund raising ah !
the gap ,,,,,,,,,,,,,,,all passengers ,,,,,,,,,